RU2345067C2 - Ингибиторы дпп-iv - Google Patents
Ингибиторы дпп-iv Download PDFInfo
- Publication number
- RU2345067C2 RU2345067C2 RU2006131597/04A RU2006131597A RU2345067C2 RU 2345067 C2 RU2345067 C2 RU 2345067C2 RU 2006131597/04 A RU2006131597/04 A RU 2006131597/04A RU 2006131597 A RU2006131597 A RU 2006131597A RU 2345067 C2 RU2345067 C2 RU 2345067C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- independently selected
- compound according
- heterocycle
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 5
- 150000001875 compounds Chemical class 0.000 claims abstract 33
- 238000006467 substitution reaction Methods 0.000 claims abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 150000002367 halogens Chemical class 0.000 claims abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims abstract 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001721 carbon Chemical group 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000005842 heteroatom Chemical group 0.000 claims abstract 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- RSRJUQRLWIKAPL-UHFFFAOYSA-N 3-amino-n-cyclohexyl-4-phenylbutanamide Chemical compound C=1C=CC=CC=1CC(N)CC(=O)NC1CCCCC1 RSRJUQRLWIKAPL-UHFFFAOYSA-N 0.000 claims 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 claims 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 claims 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 claims 1
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 claims 1
- 108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 108060000200 adenylate cyclase Proteins 0.000 claims 1
- 102000030621 adenylate cyclase Human genes 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 201000010066 hyperandrogenism Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960004738 nicotinyl alcohol Drugs 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 230000019100 sperm motility Effects 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/35—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
Abstract
Настоящее изобретение относится к новым соединениям общей формулы (I)
или их фармацевтически приемлемым солям, где Z представляет собой фенил; где Z может быть замещен одним или более R8, где R8 представляет собой галоген; R1, R4 представляют собой Н; R2, R5 представляют собой H; R3 представляет собой Н; Х выбран из группы, состоящей из S(O)2 и С(O); R6, R7 независимо выбраны из группы, состоящей из Н, (C(R29R30))m-X1-Z1 и (C(R31R32))n-X2-X3-Z2 и С1-4алкил, который несет замещение одним или более R29a, где R29a независимо выбран из группы, состоящей из R29b и Z1, при условии, что R6 и R7 выбирают таким образом, чтобы R6 и R7 не были одновременно независимо выбраны из группы, состоящей из Н, СН3, СН2СН3, СН2СН2СН3 и СН(СН3)2; R29, R29b, R30, R31, R32 независимо выбраны из группы, состоящей из Н, C1-6алкила и N(R32a)-C1-6алкила, R32a представляет собой C1-6алкил; m равно 0, 1 или 2; n равно 2; X1 независимо выбран из группы, состоящей из ковалентной связи, -C1-6алкила и -C1-6алкил-N(R33)-; X2 представляет собой -N(R35)-; X3 представляет собой -С(O)-; R33 представляет собой С1-6алкил; R35 представляет собой Н; Z1, Z2 независимо выбраны из группы, состоящей из Z3 и -C(R37a)Z3aZ3b; R37a представляет собой Н; Z3, Z3a, Z3b независимо выбраны из группы, состоящей из Т1, Т2, C1-6алкила, C1-6алкил-Т1 и C1-6алкил-Т2; Т1 представляет собой фенил; где Т1 факультативно несет замещение одним или более R38; причем R38 независимо выбран из группы, состоящей из галогена, CN, R39, C(O)NH2, S(O)2NH2, ОТ3, C(O)N(R40)T3 и Т3, Т2 выбран из группы, состоящей из С3-7циклоалкила, инданила, тетралинила, гетероцикла и гетеробицикла, причем Т2 факультативно несет замещение одним или более R41, где R41 независимо выбран из группы, состоящей из галогена, R42, OH и Т3; R39 выбран из группы, состоящей из C1-6алкила, O-C1-6алкила, S-C1-6алкила, C(O)N(R44)-C1-6алкила, S(O)-С1-6алкила и S(O)2-C1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более R45, где R45 независимо выбран из группы, состоящей из F, N(R46R47) и Т3; R42 представляет собой C1-6алкил, причем каждый C1-6алкил факультативно несет замещение одним или более R45, где R45 независимо выбран из группы, состоящей из F; R40, R46, R47 независимо выбраны из группы, состоящей из Н и C1-6алкила; R44 представляет собой Н; Т3 выбран из группы, состоящей из Т4 и Т5; Т4 представляет собой фенил, где Т4 факультативно несет замещение одним или более R51, где R51 независимо выбран из группы, состоящей из галогена, OR52, S(O)2N(R52R53), C1-6алкила; R52, R53 независимо выбраны из группы, состоящей из Н и C1-6алкила; Т5 выбран из группы, состоящей из гетероцикла С3-7циклоалкила, где Т5 факультативно несет замещение одним или более R54, где R54 представляет собой C1-6алкил; где гетероцикл обозначает кольцо циклобутана, циклопентана, циклогексана, которое может содержать двойные связи в количестве вплоть до максимального, или ароматическое или неароматическое кольцо, которое является полностью или частично насыщенным, либо ненасыщенным, и в котором по меньшей мере один атом углерода, а максимально до четырех атомов углерода, заменены на гетероатом, выбранный из группы, включающей кислород и азот, и где кольцо связано с остальной частью молекулы через атом углерода или азота; где гетеробицикл обозначает гетероцикл, как определено выше, который конденсирован с фенилом или другим гетероциклом с образованием бициклической системы колец, при условии, что следующее соединение исключено из притязаний: 3-амино-N-циклогексил-4-фенилбутирамид. Также изобретение относится к фармацевтической композиции на основе соединения общей формулы (I) и к применению их для изготовления лекарственного средства для лечения и/или профилактики состояний, при которых желательно ингибирование ДПП-IV. Технический результат: получена новая группа соединений, обладающих полезными биологическими свойствами. 5 н. и 21 з.п. ф-лы, 8 табл.
Description
Claims (26)
1. Соединение формулы (I)
или его фармацевтически приемлемая соль, отличающееся тем, что
Z представляет собой фенил; где Z может быть замещен одним или более
R8, где R8 представляет собой галоген;
R1, R4 представляют собой Н;
R2, R5 представляют собой Н;
R3 представляет собой Н;
Х выбран из группы, состоящей из S(O)2 и С(O);
R6, R7 независимо выбраны из группы, состоящей из Н, (C(R29R30))mX1-Z1 и (C(R31R32))n-X2-X3-Z2 и С1-4алкил, который несет замещение одним или более R29a, где R29a независимо выбран из группы, состоящей из R29b и Z1, при условии, что R6 и R7 выбирают таким образом, чтобы R6 и R7 не были одновременно независимо выбраны из группы, состоящей из Н, СН3, СН2СН3, СН2СН2СН3 и СН(СН3)2;
R29 R29b, R30, R31, R32 независимо выбраны из группы, состоящей из Н, C1-6алкила и N(R32a)-С1-6алкила;
R32a представляет собой C1-6алкил;
m равно 0, 1 или 2;
n равно 2;
X1 независимо выбран из группы, состоящей из ковалентной связи, -C1-6алкила и -С1-6алкил-N(R33)-;
Х представляет собой -N(R35)-;
X3 представляет собой -С(O)-;
R33 представляет собой C1-6алкил;
R35 представляет собой Н;
Z1, Z2 независимо выбраны из группы, состоящей из Z3 и -C(R37a)Z3aZ3b;
R37a представляет собой Н;
Z3, Z3a, Z3b независимо выбраны из группы, состоящей из Т1, Т2, C1-6алкила, C1-6алкил-Т1 и C1-6алкил-Т2;
Т1 представляет собой фенил; где Т1 факультативно несет замещение одним или более R38; причем R38 независимо выбран из группы, состоящей из галогена, CN, R39, C(O)NH2, S(O)2NH2, ОТ3, C(О)N(R40)T3 и Т3, Т2 выбран из группы, состоящей из С3-7циклоалкила, инданила, тетралинила, гетероцикла и гетеробицикла, причем Т2 факультативно несет замещение одним или более R41, где R41 независимо выбран из группы, состоящей из галогена, R42, OH и Т3;
R39 выбран из группы, состоящей из С1-6алкила, O-C1-6алкила, S-C1-6алкила, С(O)N(R44)-С1-6алкила, S(O)-С1-6алкила и S(O)2-С1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более R45, где R45 независимо выбран из группы, состоящей из F, N(R46R47) и Т3;
R42 представляет собой C1-6алкил, причем каждый C1-6алкил факультативно несет замещение одним или более R45, где R45 независимо выбран из группы, состоящей из F;
R40, R46, R47 независимо выбраны из группы, состоящей из Н и C1-6алкила;
R44 представляет собой Н;
Т3 выбран из группы, состоящей из Т4 и Т5;
Т4 представляет собой фенил, где Т4 факультативно несет замещение одним или более R51, где R51 независимо выбран из группы, состоящей из галогена, OR52, S(O)2N(R52R53), С1-6алкила;
R52, R53 независимо выбраны из группы, состоящей из Н и C1-6алкила;
Т5 выбран из группы, состоящей из гетероцикла С3-7циклоалкила, где Т5 факультативно несет замещение одним или более R54, где R54 представляет собой C1-6алкил;
где гетероцикл обозначает кольцо циклобутана, циклопентана, циклогексана, которое может содержать двойные связи в количестве вплоть до максимального, или ароматическое или неароматическое кольцо, которое является полностью или частично насыщенным либо ненасыщенным, и в котором по меньшей мере один атом углерода, а максимально до четырех атомов углерода, заменены на гетероатом, выбранный из группы, включающей кислород и азот, и где кольцо связано с остальной частью молекулы через атом углерода или азота;
где гетеробицикл обозначает гетероцикл, как определено выше, который конденсирован с фенилом или другим гетероциклом с образованием бициклической системы колец,
при условии, что следующее соединение исключено из притязаний:
3-амино-N-циклогексил-4-фенилбутирамид.
или его фармацевтически приемлемая соль, отличающееся тем, что
Z представляет собой фенил; где Z может быть замещен одним или более
R8, где R8 представляет собой галоген;
R1, R4 представляют собой Н;
R2, R5 представляют собой Н;
R3 представляет собой Н;
Х выбран из группы, состоящей из S(O)2 и С(O);
R6, R7 независимо выбраны из группы, состоящей из Н, (C(R29R30))mX1-Z1 и (C(R31R32))n-X2-X3-Z2 и С1-4алкил, который несет замещение одним или более R29a, где R29a независимо выбран из группы, состоящей из R29b и Z1, при условии, что R6 и R7 выбирают таким образом, чтобы R6 и R7 не были одновременно независимо выбраны из группы, состоящей из Н, СН3, СН2СН3, СН2СН2СН3 и СН(СН3)2;
R29 R29b, R30, R31, R32 независимо выбраны из группы, состоящей из Н, C1-6алкила и N(R32a)-С1-6алкила;
R32a представляет собой C1-6алкил;
m равно 0, 1 или 2;
n равно 2;
X1 независимо выбран из группы, состоящей из ковалентной связи, -C1-6алкила и -С1-6алкил-N(R33)-;
Х представляет собой -N(R35)-;
X3 представляет собой -С(O)-;
R33 представляет собой C1-6алкил;
R35 представляет собой Н;
Z1, Z2 независимо выбраны из группы, состоящей из Z3 и -C(R37a)Z3aZ3b;
R37a представляет собой Н;
Z3, Z3a, Z3b независимо выбраны из группы, состоящей из Т1, Т2, C1-6алкила, C1-6алкил-Т1 и C1-6алкил-Т2;
Т1 представляет собой фенил; где Т1 факультативно несет замещение одним или более R38; причем R38 независимо выбран из группы, состоящей из галогена, CN, R39, C(O)NH2, S(O)2NH2, ОТ3, C(О)N(R40)T3 и Т3, Т2 выбран из группы, состоящей из С3-7циклоалкила, инданила, тетралинила, гетероцикла и гетеробицикла, причем Т2 факультативно несет замещение одним или более R41, где R41 независимо выбран из группы, состоящей из галогена, R42, OH и Т3;
R39 выбран из группы, состоящей из С1-6алкила, O-C1-6алкила, S-C1-6алкила, С(O)N(R44)-С1-6алкила, S(O)-С1-6алкила и S(O)2-С1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более R45, где R45 независимо выбран из группы, состоящей из F, N(R46R47) и Т3;
R42 представляет собой C1-6алкил, причем каждый C1-6алкил факультативно несет замещение одним или более R45, где R45 независимо выбран из группы, состоящей из F;
R40, R46, R47 независимо выбраны из группы, состоящей из Н и C1-6алкила;
R44 представляет собой Н;
Т3 выбран из группы, состоящей из Т4 и Т5;
Т4 представляет собой фенил, где Т4 факультативно несет замещение одним или более R51, где R51 независимо выбран из группы, состоящей из галогена, OR52, S(O)2N(R52R53), С1-6алкила;
R52, R53 независимо выбраны из группы, состоящей из Н и C1-6алкила;
Т5 выбран из группы, состоящей из гетероцикла С3-7циклоалкила, где Т5 факультативно несет замещение одним или более R54, где R54 представляет собой C1-6алкил;
где гетероцикл обозначает кольцо циклобутана, циклопентана, циклогексана, которое может содержать двойные связи в количестве вплоть до максимального, или ароматическое или неароматическое кольцо, которое является полностью или частично насыщенным либо ненасыщенным, и в котором по меньшей мере один атом углерода, а максимально до четырех атомов углерода, заменены на гетероатом, выбранный из группы, включающей кислород и азот, и где кольцо связано с остальной частью молекулы через атом углерода или азота;
где гетеробицикл обозначает гетероцикл, как определено выше, который конденсирован с фенилом или другим гетероциклом с образованием бициклической системы колец,
при условии, что следующее соединение исключено из притязаний:
3-амино-N-циклогексил-4-фенилбутирамид.
3. Соединение по п.1, отличающееся тем, что Z возможно несет замещение 1 или 2 R8, которые могут быть одинаковыми или разными.
4. Соединение по п.1, отличающееся тем, что Z представляет собой 2-фторфенил.
5. Соединение по п.1, отличающееся тем, что R6 выбран из группы, состоящей из Н и СН3.
6. Соединение по п.1, отличающееся тем, что Х1 представляет собой ковалентную связь.
7. Соединение по п.1, отличающееся тем, что R7 представляет собой Z1.
8. Соединение по п.1, отличающееся тем, что R7 представляет собой С1-4алкил, замещенный 1-4 R29a, которые могут быть одинаковыми или разными.
9. Соединение по п.1, отличающееся тем, что R29a выбран из группы, состоящей из R29b и Z1, и где R29b представляет собой N(СН3)2.
10. Соединение по п.1, отличающееся тем, что R29a выбран из группы, состоящей из R29b и Z1, где Z1 выбран из группы, состоящей из Т1 и Т2.
11. Соединение по п.1, отличающееся тем, что Т1 представляет собой фенил, и где Т1 факультативно несет замещение одим-тремя R38, которые могут быть одинаковыми или разными.
12. Соединение по п.1, отличающееся тем, что R38 независимо выбран из группы, состоящей из F, Cl, CN, СН3, С2Н5, СН2CH2СН3, СН(СН3)2, CF3, O-СН3, O-С2Н5. S-СН3, SO2NH2, Т3 и O-Т3.
14. Соединение по п.1, отличающееся тем, что R41 выбран из группы, состоящей из ОН, СН3 и Т3;
15. Соединение по п.1, отличающееся тем, что Т3 представляет собой Т4.
16. Соединение по п.1, отличающееся тем, что Т4 представляет собой фенил, где Т4 возможно несет замещение одним-тремя R51, которые могут быть одинаковыми или разными.
17. Соединение по п.1, отличающееся тем, что R51 независимо выбран из группы, состоящей из F, Cl, O-СН3, O-С2Н5.
18. Соединение по п.1, отличающееся тем, что Т3 представляет собой Т5.
19. Соединение по п.1, отличающееся тем, что Т5 представляет собой гетероцикл, где Т5 возможно несет замещение одним или двумя R54, которые могут быть одинаковыми или разными.
20. Соединение по п.1, отличающееся тем, что R54 представляет собой СН3.
22. Фармацевтическая композиция для лечения и/или предупреждения состояний, при которых желательно ингибирование ДПП-IV, содержащая соединение по любому из пп.1-21 или его фармацевтически приемлемую соль совместно с фармацевтически приемлемым носителем.
23. Фармацевтическая композиция по п.22, содержащая одно или более дополнительных соединений или их фармацевтически приемлемых солей, выбранных из группы, состоящей из другого соединения по любому из пп.1-21; другого ингибитора ДПП-IV; сенсибилизаторов к инсулину; агонистов РАПП; бигуанидов; ингибиторов протеин тирозинфосфатазы-1B (РТР-1В); инсулина и миметиков инсулина; производных сульфонилмочевины и других веществ, стимулирующих секрецию инсулина, ингибиторов α-глюкозидазы, антагонистов рецепторов к глюкагону, глюкагоноподобного пептида (GLP-1), миметиков GLP-1 и агонистов рецепторов к GLP-1, гастроингибиторного пептида (ГИП), миметиков ГИП и агонистов рецепторов к ГИП; пептида, активирующего аденилатциклазу гипофиза (РАСАР), миметиков РАСАР и агонистов рецептора 3 к РАСАР; препаратов, снижающих содержание холестерина, ингибиторов HMG-CoA редуктазы (3-гидрокси-3-метилглютарил-коэнзим А-редуктазы); секвестрантов; никотинилового спирта, никотиновой кислоты и ее соли, агонистов РАППα (PPARα); агонистов PPAR-α/γ двойного действия, ингибиторов всасывания холестерина, ингибиторов ацил-СоА-холестерин ацилтрансферазы, антиоксидантов, агонистов РАППδ, соединений для лечения ожирения, ингибитора идеального переносчика желчных кислот и противовоспалительных препаратов.
24. Соединение или его фармацевтически приемлемая соль по любому из пп.1-21 для применения в качестве лекарственного средства для лечения и/или предупреждения состояний, при которых желательно ингибирование ДПП-IV.
25. Применение соединения или его фармацевтически приемлемой соли по любому из пп.1-21 для изготовления лекарственного средства для лечения и профилактики инсулиннезависимого сахарного диабета (Тип II), гипергликемии, ожирения, устойчивости к инсулину, нарушений обмена липидов, дислипидемии, гиперлипидемии, гипертриглицеридемии, гиперхолестеринемии, низких уровней ЛПВП, высоких уровней ЛПНП, атеросклероза, дефицита гормона роста, болезней, связанных с иммунными реакциями, ВИЧ-инфекции, нейтропении, нейрональных заболеваний, метастазирования опухолей, доброкачественной гипертрофии предстательной железы, гингивита, гипертензии, остеопороза, заболеваний, связанных с подвижностью сперматозоидов, низкой толерантности к глюкозе, устойчивости к инсулину, ее последствий, рестеноза сосудов, синдрома раздраженного кишечника, воспалительных заболеваний кишечника, включая болезнь Крона и язвенный колит, других воспалительных заболеваний, панкреатита, абдоминального ожирения, нейродегенеративных заболеваний, тревожности, депрессии, ретинопатии, нефропатии, нейропатии, «синдрома X», гиперандрогенизма яичников (синдром поликистозных яичников), диабета Типа II или дефицита гормона роста.
26. Применение соединения по любому из пп.1-21 в качестве ингибитора ДПП-IV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04005347.2 | 2004-03-05 | ||
EP04005347A EP1593671A1 (en) | 2004-03-05 | 2004-03-05 | DPP-IV inhibitors |
PCT/EP2005/002010 WO2005095343A1 (en) | 2004-03-05 | 2005-02-25 | Dpp-iv inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006131597A RU2006131597A (ru) | 2008-04-10 |
RU2345067C2 true RU2345067C2 (ru) | 2009-01-27 |
Family
ID=34924473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006131597/04A RU2345067C2 (ru) | 2004-03-05 | 2005-02-25 | Ингибиторы дпп-iv |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070197522A1 (ru) |
EP (2) | EP1593671A1 (ru) |
JP (1) | JP2007526267A (ru) |
KR (1) | KR20070007816A (ru) |
CN (1) | CN1980892A (ru) |
AU (1) | AU2005229330B2 (ru) |
CA (1) | CA2558446A1 (ru) |
MX (1) | MXPA06010097A (ru) |
NO (1) | NO20064032L (ru) |
RU (1) | RU2345067C2 (ru) |
WO (1) | WO2005095343A1 (ru) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
WO2007063928A1 (ja) * | 2005-11-30 | 2007-06-07 | Toray Industries, Inc. | 新規な非環状アミンカルボキシアミド誘導体及びその塩 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20090156465A1 (en) * | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
US20100016374A1 (en) * | 2006-04-05 | 2010-01-21 | Steven Coulton | Compounds Which Inhibit the Glycine Transporter and Uses Thereof |
BRPI0709984A2 (pt) | 2006-04-12 | 2011-08-02 | Probiodrug Ag | inibidores de enzima |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
JP5323684B2 (ja) | 2006-05-04 | 2013-10-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多形体 |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2008130151A1 (en) * | 2007-04-19 | 2008-10-30 | Dong-A Pharm. Co., Ltd. | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity |
PT2264009T (pt) | 2008-03-12 | 2019-04-29 | Ube Industries | Composto do ácido piridilaminoacético |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
PL2415763T3 (pl) | 2009-03-30 | 2016-05-31 | Ube Industries | Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry |
PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
EP2504002B1 (en) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
EP2418196A1 (en) * | 2010-07-29 | 2012-02-15 | IMTM GmbH | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors |
DK3400944T3 (da) | 2010-11-08 | 2020-10-12 | Albireo Ab | Ibat-inhibitorer til behandling af leversygdomme |
US20120114588A1 (en) * | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
SG11201601682RA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazole derivatives as immunomodulators |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
CN114213356A (zh) | 2015-03-10 | 2022-03-22 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物 |
CN107427476A (zh) * | 2015-03-10 | 2017-12-01 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物 |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
US20190038611A1 (en) * | 2015-09-09 | 2019-02-07 | The Regents Of The University Of California | Novel CYP34A-Specific Inhibitors and Methods of Using Same |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
CN111107902A (zh) * | 2017-03-14 | 2020-05-05 | 丹娜法伯癌症研究所 | Bax活化的用于诱导细胞死亡的小分子致敏 |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
JP2020536872A (ja) | 2017-10-11 | 2020-12-17 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 3−置換1,2,4−オキサジアゾールの結晶形態 |
EA202090746A1 (ru) | 2017-11-03 | 2020-08-17 | Ориджен Дискавери Текнолоджис Лимитед | Двойные ингибиторы путей tim-3 и pd-1 |
AU2018360389A1 (en) | 2017-11-06 | 2020-05-07 | Aurigene Oncology Limited | Conjoint therapies for immunomodulation |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
SG11202012151XA (en) | 2018-06-20 | 2021-01-28 | Albireo Ab | Crystal modifications of odevixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20220109450A (ko) | 2019-12-04 | 2022-08-04 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도 |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455271A (en) * | 1992-06-18 | 1995-10-03 | The Scripps Research Institute | Tight-binding inhibitors of leukotriene A4 hydrolase |
DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
AU2002310465B2 (en) * | 2001-06-20 | 2006-06-15 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
EP1406872B1 (en) * | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
AR043515A1 (es) * | 2003-03-19 | 2005-08-03 | Merck & Co Inc | Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica |
-
2004
- 2004-03-05 EP EP04005347A patent/EP1593671A1/en not_active Withdrawn
-
2005
- 2005-02-25 RU RU2006131597/04A patent/RU2345067C2/ru not_active IP Right Cessation
- 2005-02-25 MX MXPA06010097A patent/MXPA06010097A/es unknown
- 2005-02-25 JP JP2007501183A patent/JP2007526267A/ja not_active Withdrawn
- 2005-02-25 CN CNA2005800137836A patent/CN1980892A/zh active Pending
- 2005-02-25 CA CA002558446A patent/CA2558446A1/en not_active Abandoned
- 2005-02-25 WO PCT/EP2005/002010 patent/WO2005095343A1/en active Application Filing
- 2005-02-25 AU AU2005229330A patent/AU2005229330B2/en not_active Expired - Fee Related
- 2005-02-25 KR KR1020067020710A patent/KR20070007816A/ko active Application Filing
- 2005-02-25 US US10/591,108 patent/US20070197522A1/en not_active Abandoned
- 2005-02-25 EP EP05715551A patent/EP1758861A1/en not_active Withdrawn
-
2006
- 2006-09-07 NO NO20064032A patent/NO20064032L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
MARUGG J L ET AL: "Selective catch and release of synthetically useful phosphine ligand", TETRAHEDRON LETTERS, ELSEVIER SCIENCE. PUBLISHERS, AMSTERDAM, NL, vol.44, no.40, 29.09.2003, pages 7537-7540. MOREE, WILNA J. ET AL: "Synthesis of peptidosulfinamides and peptidosulfonamides: Peptidomimetics Containing the Sulfinamide or. Sulfonamide Transition-State Isoster", JOURNAL OF ORGANIC CHEMISTRY, 60(16), 5157-69, 1995. * |
Also Published As
Publication number | Publication date |
---|---|
MXPA06010097A (es) | 2007-06-15 |
CN1980892A (zh) | 2007-06-13 |
RU2006131597A (ru) | 2008-04-10 |
JP2007526267A (ja) | 2007-09-13 |
NO20064032L (no) | 2006-11-08 |
AU2005229330B2 (en) | 2008-12-18 |
AU2005229330A1 (en) | 2005-10-13 |
WO2005095343A1 (en) | 2005-10-13 |
EP1758861A1 (en) | 2007-03-07 |
CA2558446A1 (en) | 2005-10-13 |
US20070197522A1 (en) | 2007-08-23 |
EP1593671A1 (en) | 2005-11-09 |
KR20070007816A (ko) | 2007-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2345067C2 (ru) | Ингибиторы дпп-iv | |
JP6233454B2 (ja) | Trk阻害化合物 | |
RU2006140797A (ru) | Производные бензиламина 1-[(3r)-амино-4-(2-фторфенил)-бутил]-пирролидин-(2r)-карбоновой кислоты и родственные соединения в качестве ингибиторов дипептидил-пептидазы iv (дпп-iv) для терапии сахарного диабета второго типа | |
JP6144913B2 (ja) | 代謝異常の治療に使用されるgタンパク質共役受容体43(gpr43)作動薬としてのピロリジンカルボン酸誘導体、医薬組成物および方法 | |
RU2006140795A (ru) | Ингибиторы дпп-iv | |
RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
RU2006140796A (ru) | Ингибиторы дпп-iv | |
CA2820854C (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
RU2005139525A (ru) | N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы | |
WO2013161919A1 (ja) | Trk阻害化合物 | |
RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
JP2008513498A5 (ru) | ||
EA018894B1 (ru) | N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция | |
EA007060B1 (ru) | N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы | |
RU2004119037A (ru) | Гетероциклические соединения и способы применения | |
CR7928A (es) | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension | |
RU2012117786A (ru) | Новое производное фенола | |
EA032104B1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
US20170015641A1 (en) | Dicarboxylic acid compound | |
TW523504B (en) | Biphenylamidine derivatives | |
JP2008524145A5 (ru) | ||
US9273041B2 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
JP2010504321A5 (ru) | ||
JP2007001946A (ja) | ピロリジン誘導体 | |
JP6430246B2 (ja) | 微小管重合阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090226 |